PsychedelicNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption process and quotes one of the applicants, Laurie Brooks, on the approval, who stated, “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgment of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional . . . as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin for therapeutic use, to help with the pain they are experiencing without having to petition the government for months to gain permission.”

To view the full article, visit http://ibn.fm/bFibA

About Cybin Corp.

Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About PsychedelicNewsBreaks

PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances IP Portfolio With EPO Notice of Intent to Grant Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on novel formulations and drug…

2 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a letter from the FDA Office of Generic…

3 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S.…

3 weeks ago

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.…

4 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic…

1 month ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD,…

1 month ago